Poor
Not Aligned
Patient Risk:
Moderate
Summary
Only a subset of claims is supported by the provided label excerpts (e.g., HMG-CoA reductase mechanism and statin-associated myopathy with muscle aches/weakness). Multiple additional mechanistic and supplement-related claims (CoQ10, HMB, muscle growth/repair, physical performance, study/patent/generic availability) are not supported by the supplied prescribing information. Safety-critical labeling sections such as contraindications/boxed warnings/dosing are not evaluated.
Category Scores
Accurate Statements
Lipitor works by inhibiting the enzyme HMG-CoA reductase, which plays a role in cholesterol production.
12.1 Mechanism of Action: 'selective, competitive inhibitor of HMG-CoA reductase' and description of cholesterol synthesis/precursor mevalonate
Statins like Lipitor can cause muscle damage and weakness as a side effect.
5.1 Skeletal Muscle: 'Atorvastatin... occasionally causes myopathy, defined as muscle aches or muscle weakness...'
Statins like Lipitor can cause muscle pain as a side effect.
5.1 Skeletal Muscle: myopathy defined as 'muscle aches' (and related reporting/discontinuation guidance)
Unsupported Statements
Lipitor is a statin medication used to lower cholesterol.
Partially supported at best by the provided indication excerpt (lipid-altering therapy adjunct to diet) and mechanism; the label excerpt supplied does not explicitly state the phrasing 'used to lower cholesterol' as an indication.
Lipitor is a statin medication used to prevent heart disease.
The provided indication excerpt discusses risk for atherosclerotic vascular disease/CHD-related risk factors, but does not explicitly support 'prevent heart disease.'
Statins like Lipitor can cause muscle fatigue as a side effect.
The provided label excerpt discusses myopathy/muscle aches or weakness and diffuse myalgias, but does not mention 'muscle fatigue.'
The described muscle damage can impede physical performance.
The provided label excerpt does not describe impacts on physical performance.
The described muscle damage can potentially impair the body's ability to grow and repair muscle tissue.
The provided label excerpt does not discuss muscle growth/repair.
Statins have been shown to interfere with the body's natural production of Coenzyme Q10 (CoQ10).
No CoQ10 statements appear in the provided label sections.
Statins have been shown to interfere with the body's natural production of HMB (beta-Hydroxy beta-Methylbutyrate).
No HMB statements appear in the provided label sections.
Supplementing with CoQ10 may help counteract muscle damage and weakness associated with statin use.
No supplement guidance (including CoQ10) appears in the provided label sections.
Supplementing with HMB may help counteract muscle damage and weakness associated with statin use.
No supplement guidance (including HMB) appears in the provided label sections.
The findings supporting CoQ10 and HMB supplementation are based on animal studies and human trials with limited sample sizes.
No CoQ10/HMB evidence or study descriptions appear in the provided label sections.
A study on the impact of Lipitor on muscle protein synthesis found no significant effects in healthy individuals.
No such study or muscle protein synthesis claim appears in the provided label sections.
Lipitor's patent expired in 2012.
Patent status is not addressed in the provided label sections.
Generic versions of Lipitor are widely available.
Generic availability is not addressed in the provided label sections.
Contradictions
Important Omissions
Contraindications and boxed warnings (and related safety requirements) were not evaluated against the label.
Importance:
Moderate
Dosage and administration details (including any label-required maximum dosing/with interacting agents) were not evaluated against the label.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Multiple safety-relevant and physiology/supplement claims (CoQ10/HMB, muscle growth/repair, physical performance, muscle fatigue) are not supported by the provided label excerpts, and contraindications/boxed warnings/dosing safety were not evaluated.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Many claims are not supported by the provided prescribing information, including CoQ10/HMB mechanistic and supplementation assertions and several unsupported extrapolations about muscle function.
Suggested Improvement
Limit claims to content directly supported by the provided label excerpts (e.g., mechanism via HMG-CoA reductase inhibition; myopathy characterized as muscle aches/weakness with risk factors/monitoring and discontinuation guidance). Remove or revise unsupported CoQ10/HMB, muscle performance/growth/repair, study/patent/generic availability assertions unless corresponding label text is provided.